Sanofi will acquire Blueprint Medicines for $9.1 billion in cash, plus up to $400 million in earnouts, marking Sanofi's third major acquisition in 2025 as it diversifies beyond its reliance on Dupixent. Blueprint stockholders will receive $129 per share, a 23.3% premium, plus contingent value rights. The acquisition aims to leverage Sanofi's rare disease expertise to expand the market reach of Blueprint's Ayvakit, a systemic mastocytosis drug that generated $150 million in Q1 sales.
Sanofi's agreement to acquire Blueprint Medicines for $9.1 billion in cash, supplemented by up to $400 million in earnouts, represents a significant strategic initiative to diversify its revenue streams and reduce over-reliance on its leading anti-inflammatory drug, Dupixent. This transaction is Sanofi's third major acquisition in 2025, following Dren Bo and Vigil Neuroscience, highlighting an aggressive inorganic growth strategy aimed at bolstering its portfolio, a move deemed necessary following recent clinical setbacks and the €10 billion sale of a controlling stake in its consumer health unit. For Blueprint stockholders, the offer of $129 per share signifies a 23.3% premium over the prior closing price, with additional potential upside from contingent value rights tied to milestone payments. The primary driver for this acquisition appears to be the synergistic potential of combining Sanofi's established expertise in rare diseases with Blueprint's systemic mastocytosis drug, Ayvakit, which recorded approximately $150 million in Q1 sales, suggesting a pathway to accelerated market penetration and revenue growth for the acquired asset.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.65
Ticker Sentiment
